Literature DB >> 2208135

Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.

L D Recht1, T W Griffin, V Raso, A R Salimi.   

Abstract

The cytotoxic effects of an antihuman transferrin receptor monoclonal antibody-ricin A-chain conjugate (anti-TfR-A) immunotoxin on glioma cells were assessed in vitro. Five human glioma cell lines were studied; three were derived from surgical explants (MG-1, MG-2, MG-3) and two were well characterized established glioma cells (U-87 MG, U-373 MG). The C6 rat glioma line served as a nonhuman control. One of six lines (U-373) expressed glial fibrillary acidic protein, as assessed by immunohistochemistry. All five human lines expressed human transferrin receptor, as assessed by flow cytometry; no human transferrin receptor was demonstrable on rat C6 cells. Potent inhibition of protein synthesis was found after an 18-h incubation with anti-TfR-A. Fifty % inhibitory concentration (IC50) values for human glioma cells ranged from 1.9 X 10(-9) to 1.8 X 10(-8) M. In contrast, no significant inhibition of leucine incorporation was observed when anti-TfR-A was tested on rat cells (IC50 greater than 10(-7) M) or when a control immunotoxin directed against carcinoembryonic antigen was substituted for anti-TfR-A on human glioma cells (IC50 greater than 10(-7) M). Coincubation with the carboxylic ionophore monensin (10(-7) M) decreased the IC50 of anti-TfR-A against human glioma lines from 16- to 842-fold (range, 7.0 X 10(-12) to 1.5 X 10(-10) M). In contrast, an IC50 of greater than 10(-7) M was obtained when C6 cells were incubated with anti-TfR-A and monensin. Anti-TfR-A immunotoxins potentiated by monensin are extremely potent in vitro cytotoxins for human glioma cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208135

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Authors:  Patrick P Ng; Jay S Dela Cruz; David N Sorour; James M Stinebaugh; Seung-Uon Shin; Daniel S Shin; Sherie L Morrison; Manuel L Penichet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

2.  Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion.

Authors:  Robert C Rostomily; Donald E Born; Richard P Beyer; Jinghua Jin; Ellsworth C Alvord; Andrei M Mikheev; Russell T Matthews; Catherine Pan; Leila Khorasani; Josh A Sonnen; Thomas J Montine; Min Shi; Jing Zhang
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

Review 3.  Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.

Authors:  Vidyalakshmi Chandramohan; Duane A Mitchell; Laura A Johnson; John H Sampson; Darell D Bigner
Journal:  Future Oncol       Date:  2013-07       Impact factor: 3.404

Review 4.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

5.  Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.

Authors:  Edward Rustamzadeh; Daniel A Vallera; Deborah A Todhunter; Walter C Low; Angela Panoskaltsis-Mortari; Walter A Hall
Journal:  J Neurooncol       Date:  2006-05       Impact factor: 4.130

6.  Immunotoxin therapy of leptomeningeal neoplasia.

Authors:  S Walbridge; S M Rybak
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 7.  Toxin-based targeted therapy for malignant brain tumors.

Authors:  Vidyalakshmi Chandramohan; John H Sampson; Ira Pastan; Darell D Bigner
Journal:  Clin Dev Immunol       Date:  2012-02-09

8.  Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.

Authors:  Ran Liu; Yonglu Wang; Xueming Li; Wen Bao; Guohua Xia; Wei Chen; Jian Cheng; Yuanlong Xu; Liting Guo; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2015-05-22       Impact factor: 4.162

9.  Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion.

Authors:  Mingzhi Han; Ran Xu; Shuai Wang; Ning Yang; Shilei Ni; Qing Zhang; Yangyang Xu; Xin Zhang; Chao Zhang; Yuzhen Wei; Jianxiong Ji; Bin Huang; Di Zhang; Anjing Chen; Wenjie Li; Rolf Bjerkvig; Xingang Li; Jian Wang
Journal:  Neoplasia       Date:  2018-05-03       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.